Kyle Bass Is ‘Frustrated’ by Shire’s Lialda Patent Ruling

  • ‘The system must be fixed,’ hedge fund manager Bass says
  • Bass criticizes drug prices, Shire’s Dublin headquarters

Hedge fund manager Kyle Bass expressed frustration that the U.S. Patent and Trademark Office upheld the only patent covering Shire Plc’s colitis drug Lialda and argued that “the system must be fixed.”

To continue reading this article you must be a Bloomberg Professional Service Subscriber.